JPS61225126A - Medicinal composition comprising inorganic mineral compound - Google Patents

Abstract

(57) [Summary] This bulletin contains application data before electronic filing, so abstract data is not recorded.

Description

DETAILED DESCRIPTION OF THE INVENTION The present invention relates to the treatment of various skin diseases including fungal infections;
Concerning the treatment of various types of inflammation and internal diseases. In some cases, the present invention relates to the treatment of skin, inflammation and internal diseases using pharmaceutical compositions for topical application or ingestion consisting of aluminum, iron, magnesium and other mineral compounds.

Examples of skin diseases that can be treated by the present invention are xerosis, dermatitis, phthisis, eczema, and fish! iAi Trout, L, Wasp, Acne, Fungal infection, Rash+,! iV, skin rash, scleroderma, hair loss (excluding i! legendary male baldness)
, pigmented tJ9 macules/thorns, and cysts. It can also treat superficial fungal infections of the skin, toenails, and fingernails.

Inflammatory disease Φ11” that can be treated with the composition of the present invention
These include one or more of the skin diseases listed above, as well as hemorrhoids, inflammatory skin diseases and similar conditions.

Specific skin diseases and inflammatory conditions to be treated are described below, but are not meant to be limiting.

Cyst: An abnormal cyst containing gas, liquid, or semi-solid material, including dermal cysts such as inclusion cysts or epidermal cysts of endophytic cysts.

Dermatitis: Inflammation of the skin of various causes, including skin sensitive to light (sunlight), chemicals, perfumes, allergies to various plants and animals; contact dermatitis, exfoliative Includes dermatitis, seborrheic dermatitis, and eczema.

Hemorrhoids: A condition of varicose veins in external hemorrhoids that cause painful swelling in the anus.
It is an internal hemorrhoid if the swollen vein is submucosal within the external sphincter, and an external hemorrhoid if the dilated vein forms a mass that reaches outside the sphincter.

Pigmented nevus (mole): Includes benign true iron nevus and compound nevus.

Psoriasis: A condition characterized by a localized, solitary, and confluent silvery-scaly rash, occurring primarily on the elbows, knees, scalp, and trunk.

The superficial filamentous fungal infections treated in the present invention include Linea 7 in various parts of the monthly salary, such as nail blight, head blight,
Includes groin meridian leukemia, leukoplakia, and foot leukoplakia.

Many of the conditions mentioned above have been treated in a variety of ways, such as surgically, topically and circumferentially (with a conventional regimen for therapeutic purposes). For an overview of these methods, see The Merck Manual. (The Merc, kMan+Summer Al)
See 4th edition (1982). The methods and compositions of the invention represent a significant advance over the conventional treatments described above.

The compositions of the present invention may be administered in convenient topical, oral, or rectal forms in suitable pharmaceutical vehicles or as powders. can.

Suitable pharmaceutical excipients depending on the type of formulation desired are well known in the art. Thus, for example, tablets, capsules,
Oral IJ (molded liquid or powder formulations, topical liquid and powder formulations, topical lotions, creams, ointments, salves)
, as well as suppositories can be prepared as needed.

Pharmaceutical formulations of ointments are conveniently determined empirically by those skilled in the art of formulating pharmaceutical formulations.

Also included in the provision of formulations in the present invention are dietary mineral supplements that are taken by patients by supplementing their daily mineral intake. Such provision is typically in the form of orally ingestible formulations such as tablets and capsules.

Each component present is non-toxic so that the absolute amount of active ingredient present in any dosage unit or application may or may not exceed that amount appropriate for the rate and method of administration employed. It is well understood that it is desirable that the absolute amount of the active ingredient be sufficient to achieve the required rate of administration by increasing or decreasing the number of doses or applications. Additionally, the rate of administration will depend on the condition being treated, the type of pharmaceutical formulation used, and the desired pharmacological effect.

Veterinary formulations and formulations are also within the scope of this invention. Suitable formulations include, but are not limited to, those described above for human use:
Includes feed supplements, feed additives, chewable aromatic tablets and capsules. A preferred form is a combination of aluminum compounds, iron, magnesium and other elements with animal feed for injection in the form of mash, pellets, granules or other convenient types. It may also contain vitamins, minerals, I) biological substances, antioxidants, and other pharmaceutically active compounds of the type found in livestock feed.

Essential ingredients in the pharmaceutical compositions and therapeutic methods described herein are mineral compounds and inorganic oxides, which include -■ oxides of aluminum and magnesium, and iron (in the form of iron hydroxide). ), oxides or hydroxides of silicon, sodium and potassium for minor components, and trace amounts of other elements such as calcium, zinc and copper. A more detailed analysis will be provided later.

The particular mixture of inorganic mineral compounds used in the present invention is isolated from Nevada ore. The ore is removed from the earth, ground into a fine powder, sized, treated with a small amount of sulfuric acid, and heated to form a suspension. The pII value is adjusted with a base such as ammonium hydroxide, filtered, dried and ground again. Full details of how the ore described above is processed to obtain the desired products are described below.

According to X-ray diffraction analysis and atomic absorption spectroscopy, the composition is defined as follows.

Composition 11 ratio Part by weight Ammonium sulfate 83.0 198.0 Aluminum oxide permanent 8] (Oll) 3 7.25 17.3 Magnesium oxide L MgO 1,994,7 Iron Fe
3.33 7.9 Silicon dioxide Sing Q, 62 1.5
Sodium hydroxide Na011 0.42
1.0 Potassium hydroxide KOJI O,4
61.1 Mountain water (105°F - approx. 40.6°C/month 1□0
2.53 6.0 traces of calcilyl 11, zinc and copper were detected. The proportions of the various components mentioned above can vary from the values given above. That is, from the above values, aluminum and magnesium oxides and iron are ±
Up to 1.5%, and other oxides and hydroxides can vary by ±0.5%. Unless otherwise specified, parts and percentages herein are by weight.

Preparation of Risan Mineral Powder A typical method for producing the inorganic mineral powder used in the present invention will be described below.

After removing up to 2 feet of soil, the ore is removed by scour and passed through a show crusher to level out the mesoche dimensions and remove any existing lumps.
) to remove.

(2) The ore is then crushed and the mesh size is further reduced to at least 140 mesh (Tyler) sieves.

A solution consisting of 414% (3111,5O) and 86% water (deionized water) was poured into a container or Pfaudler.
ler) Mix in the tank. Water from the groundwater table below the surface of the mining area can be received and used. After carrying out the above treatment, each solution 1.87! Fine ore is added to the solution at a ratio of 1.5 lbs. of ore to 1.5 lbs. of ore. The ratio of ore to solution in Section III is limited by the dimensions of the container used, and any volume can be used. Heating, pressurizing, and agitating the contents of the processing vessel reduces recovery time.

(4) The aqueous ore mixture is then heated to at least 250' F.
(approximately 121° C.) and suspend the ore until the ore pulp changes to a light tan color. A scan can be performed to ensure that all elements to be collected are placed in suspension. Stirring the ore in solution increases the rate of removal of the elements into suspension. However, this treatment is not a necessary requirement for successful recovery of the final product.

(5) After each element is in the suspension, heat is turned off, and each element in the suspension and pulp (which falls to the bottom of the container)
Leave the solution containing the mixture to cool overnight.

(6) Then, by filtration using Yo 541 filter paper,
Separate the solution from the pulp. Other filtration can also be used.

(7) Next, this solution was added to 26° Baume's small ammonium oxide J, (N 11 , 0
11') carefully. The solution is stirred during this addition to avoid too much heat generation or any other undesirable reactions. While performing this operation,
Add the pTI probe into the solution from time to time to pl+7.5-8.
．． Keep it at 0 (never go below 7.5)
.

If each of the above steps has been carried out properly, the precipitate will be dark brown in color.

(8) Let the solution stand for at least 4 hours, preferably overnight. The ambient temperature solution is then filtered again using Floor 541 filter paper.

(9) Remove the product from the filter paper, place it in a flat rectangular clean heat-resistant (PYl?EX) container, spread the product evenly to ensure homogeneous drying, and then place the container at 255°
Dry the product by placing in an oven dryer at F (approximately 124°C). A rotary dryer can also be used.

00) After drying, the product is preferably placed in a sealed container (desiccator) to prevent absorption of moisture from the air and to avoid clumping. The material is passed through a plate pulverizer to 1100 mesochs (Tyler). This allows for the provision of various types of pharmaceutical formulations.
ient) facilitates mixing with bases or placement into capsules.

One of the above formulations is applied to the diseased area if topical application is indicated, followed by maintaining contact, often with a bandage, until the symptoms improve. let For hemorrhoids or other inflammatory conditions in the anorectal area, apply petroleum ointments or bases or insert suppositories.

Inui Ka? For dermatitis, pigmented nevi, cysts, a water-soluble cream base that is blended with the formulation and applied into the skin is preferred. Fungal infections, pigmented nevi and cysts, especially in the area of the toenails and fingernails, are advantageously treated with petroleum ointments. The powder according to the invention is conveniently sprinkled onto the desired area. on the other hand,
Capsules and tablets are taken orally.

Suitable ointment bases and oily bases for preparing the topically applied pharmaceutical compositions according to the invention are selected. Said bases include animal fats, vegetable fats, petroleum hydrocarbons, silicones, absorption bases, emulsion bases, water-soluble bases.

Suitable bases and procedures for preparing ointments are available from Remington's Pharmaceutical Sciences (Remi
ngton'sPharmaceutical 5
sciences), pp. 525-543, Masoku Publishing (M
Ack Publishing (1965).

The present invention will be explained in more detail along the following pharmaceutical prescriptions.

Using a steel spatula and a glass ointment slab, mix inorganic mineral powder and Aloe V
eraGel) or petroleum jelly (Vaseline) paste in equal parts to produce a smooth translucent ointment.

Creaming - Using a spatula and an ointment slab, equal parts by weight of inorganic mineral powder and Dermabase cream ointment are mixed to produce a smooth light brown cream ointment. When using, rub it on and it will be absorbed into the skin・υ
-ru.

Kaimi inorganic minerals are finely ground, sized into a free-flowing powder, and packaged in 4 ounce (approximately 113 g) shaker containers. If necessary, a suitable diluent and desiccant may be included.

Adjust the active ingredient content per capsule by adjusting the content.

Hereinafter, the pharmaceutical composition and treatment method according to the present invention will be explained in detail with reference to Examples.

Example 1: Treatment of Hemorrhoids A topical cre-1 was prepared using a mineral compound dispersed in a palliative (or emollient) base.

The paste contained the following ingredients.

1 Pass ■Kaki-) (茫) ff11
m”10ゝaluminum oxide permanent product 3.7 17.6
Iron Fe 2.285
10.9 Magnesium oxide L MgO1,0054,8
Silicon dioxide 5iOz O,:H1,5 sodium hydroxide') MuNa011 0.2] 1
．． 0 Potassium Hydroxide [0110,231,0 Copper, Zinc and Calcium Trace Mil! (: 4 ri) Weight % of Pace 1 after mixing with mineral compound and relaxing base equal to 50% of the total volume ( 10*) Part by weight of mineral compound alone Relaxing base 50.0 Self-sansui (1
05°F - about 40.6°C) 1.265 ammonium sulfate (N11.) 2504 Amount to make 100% - Victim □ Give the paste of Example 1 to a patient suffering from acute inflammatory internal and external hemorrhoids and apply the paste to the affected area. The patient was instructed to apply the paste topically on a daily basis. After 4 weeks, the previously felt itching and pain in the involved rectal tissue had subsided, and the size of the swollen tissue had decreased by approximately 75%.

The paste of Example 1 was given to a patient who had a history of bleeding fissure recti for 2 to 3 years, and the paste was applied topically to the affected area once a day to treat symptoms. The patient was instructed to continue applying the drug until the condition improved. After 10 days, the patient reported 9 days of bleeding.
It decreased by 0%. After continued treatment, the symptoms disappeared.

A man with a fungal infection has intermittently treated his foot with every available medication without success. Leprosy was observed on the sole of the left foot and on the thick, loose half of the nail of the first toe. The claw of the left first toe could be easily lifted from the underlying skin.

An ointment was prepared with 50 parts by weight of the mineral powder described in Example 1 uniformly dispersed in 50 parts by weight of petroleum celery (petrolatum jelly) base. The patient was given an ointment and instructed to apply the ointment to the toes and feet, followed by bandaging. The ointment was kept in place for 2-3 days and then removed with a bandage and the foot was left untreated for 2 weeks. This operation was repeated four more times.

When the patient was examined again by a dermatologist, no abnormalities were found on the sole of the patient's left foot, and the nail on the first toe of the patient's left foot was firmly fixed. Cultures on mycobiotic agar taken from the left foot and first toe nail showed no growth. The patient did not experience any problems again.

Example - bt xian 2ii OMe Liao The ointment prepared in Example 4 was given to a Caucasian male with a history of xerosis lesions on the extremities and inguinal area for the past 3 years. Following the procedure of Example 4, topical application of the ointment was applied over a period of 2 weeks in 4 increments. At the end of treatment, the xiro lesions were cured and the epidermal tissue became smooth and clean.

EXAMPLE - PROGRESSION OF A NEVUS - A patient was examined in which a pigmented nevus on the forelimb had grown proliferatively from its initial small size to approximately three times its original size. The color of the nevus changed from light brown to gray, and its 1IJ1 texture went from smooth to coarse and granular.

These changes occurred over approximately 60 days.

The ointment of Example 4 was applied topically once and bandaged.

Approximately 2 days later, the affected area was examined. The area has been cleaned and the previously fixed diseased tissue has been removed.
And 24 hours after the single application, no evidence of inflammation or abnormality was observed on the smooth skin surface.

Second 1 ---- Jijide! ：三人ふ(・-の-组用）Using an inorganic mineral powder containing the following ingredients, QQ-7 capsules were manufactured.

[--1-----M fat system Jusei Ore Aluminum oxide permanent product AI (Oll) 33.7 17.3
Iron Pe 3.33
7.9 Magnesium oxide MgO1,994,T゛ Silicon dioxide 5io20.62 1.5 Sodium hydroxide Na0II O,421,0 Potassium hydroxide KOII O,461,1
The mineral powder contained trace amounts of copper, zinc and calcium, and a total amount of ammonium sulfate (NI+4) SO2.

The powder described by Oll was placed in size 4 capsules.

Each capsule contained 231.2 mg of powder. No fillers, additives or diluents were used.

We took a case of a male patient who was suffering from pain, was unable to walk without a cane, and had painful and stiff joints. His condition had worsened and he was unable to stand upright even for short periods of time.

The patient began administering the capsules of Example 7 at 7 capsules per day. Clear effects appear in 2-3 days,
After three weeks of treatment, the patient was able to walk a distance of half a fill (approximately 0.8 km) without the use of a cane. This outcome was something the patient had not been able to do for the past 3 years. According to patient complaints, there were no adverse effects.

Thereafter, the intake was reduced to 3 capsules per day.

Example 9: Treatment of infectious mononucleosis A woman who had been in poor health for about 12 years was diagnosed with infectious mononucleosis caused by the Epstein-Bar virus. Symptoms are high fever, sore throat, headache, fatigue and general lymph node disease.

When this patient started taking four capsules of Example 7,
Overall sensation improved within 2 days. The patient's condition continued to improve, and symptoms of fatigue completely disappeared.

Example ↓ (1-i
istalic) A woman suffering from a lack of interlocking was diagnosed with spasmodic colitis. The patient was given four capsules of Example 7 per day for two weeks. After this period, intestinal motility and sphere count 1 returned to normal.

Example uL Niji (η11nu? ≧-nM) For 8 years, a woman had been suffering from severe emphysema and was essentially bedridden.She received 4 capsules of Example 7 per CI day. The patient's doctor reported that within four weeks, the patient's doctor reported that the veins from which the liquid material was extracted became easier to find, the red and white blood cell counts returned to normal, and The resting pulse rate was 80-59 per minute. The patient reported that he could no longer stay on the floor, was able to walk around the house, and had a marked improvement in his breathing. It was seen.

Shira 12: Treatment of Ni+ Prostate and Bone Cancer A patient was diagnosed with malignant prostate cancer and developed an additional swollen mass in the right pelvic wall over a 3-year period. The patient continued to experience a general decline in health and vitality until he was unable to walk without pain. The patient's general condition worsened and even required pain medication.

The patient took the capsules of Example 7 (7 capsules per day).
Within three weeks, the size of the swollen mass decreased and the pain associated with it decreased. After three months of treatment, the tumor mass was almost no longer palpable. The patient's general physical fitness also improved significantly, and some of the gray hair on his body and head returned to its original black color. The patient's mood is
I always feel better when I take capsules than when I don't.

庸113：ノLnーQj台板 We took up a patient who was diagnosed with terminal cancer and whose diagnosis was confirmed through examination and surgery, but who had not received any treatment. Approximately six months after diagnosis, the patient began taking the capsules of Example 7 (12 capsules per day) and her mental attitude, appetite, and physical strength improved considerably. After 7 months of treatment, a CAT scan showed that there was a measurable reduction in most swelling. 1
After 1 month, the patient felt better and the pancreatic cancer showed continuous reduction with a final residual volume of 80%. The cancer in the pancreatic lymph nodes, lungs, lungs and small intestine was no longer present and had disappeared.

Charcoal ■: Frequent epidermal gaff (7) A male patient with a mass on the left side of his neck had most of the mass removed surgically, and the mass was diagnosed as epidermoid (metastasis). ) Carcinoma. Because not all of the diseased tissue could be removed, the patient's condition was considered terminal.

The patient took the capsules of Example 7 for 26 days (9 capsules per day). A subsequent biopsy of the nasopharynx revealed no evidence of malignancy. The patient continued to take the capsules for about 4 months, and at the same time received cobalt radiation therapy. Radiation therapy causes significant weight loss, but
Inorganic mineral dietary supply is believed to be responsive to the condition of non-cancer patients.

Claims (1)

[Claims] 1. Aluminum oxide hydrate: about 18 parts by weight Iron: about 11 parts by weight Magnesium oxide: about 5 parts by weight Silicon dioxide: about 1.5 parts by weight Sodium hydroxide: about 1 part by weight Potassium hydroxide: about 1 part by weight and containing trace amounts of copper, zinc and calcium, further containing residual amounts of ammonium sulfate, and optionally a pharmaceutically acceptable carrier or diluent, in an animal with a skin disease ( A method of treating skin diseases consisting of feeding the skin to humans (other than humans). 2. Aluminum oxide hydrate: about 18 parts by weight Iron: about 11 parts by weight Magnesium oxide: about 5 parts by weight Silicon dioxide: about 1.5 parts by weight Sodium hydroxide: about 1 part by weight Potassium hydroxide: about 1 part by weight; copper; administering to an animal (other than a human) with an inflammatory condition an effective amount of a mixture containing trace amounts of zinc and calcium, further containing a balance of ammonium sulfate, and optionally a pharmaceutically acceptable carrier or diluent; A method of treating inflammatory conditions consisting of: 3. The method according to claim 2, wherein the inflammatory condition is an inflammatory skin disease. 4. Aluminum oxide hydrate: about 18 parts by weight Iron: about 11 parts by weight Magnesium oxide: about 5 parts by weight Silicon dioxide: about 1.5 parts by weight Sodium hydroxide: about 1 part by weight Potassium hydroxide: about 1 part by weight; copper; An effective amount of a mixture containing trace amounts of zinc and calcium, further containing residual amounts of ammonium sulfate, and optionally a pharmaceutically acceptable carrier or diluent, is administered to hemorrhoidal tissue of an animal with hemorrhoids (other than humans). A method of treating hemorrhoids, which consists in giving it topically. 5. The method according to claim 1, wherein the skin disease is psoriasis. 6. Claim 1, wherein the skin disease is dermatitis.
The method described in section. 7. Claim 1, wherein the skin disease is acne
The method described in section. 8. The method according to claim 1, wherein the skin disease is a filamentous fungal infection. 9. The method according to claim 1, wherein the skin disease is tinea pedis. 10. The method according to claim 1, wherein the skin disease is tinea unguium. 11. Claim 1, wherein the skin disease is a birthmark.
The method described in section. 12. The method according to claim 1, wherein the skin disease is cyst. 13. Aluminum oxide hydrate: about 18 parts by weight Iron: about 11 parts by weight Magnesium oxide: about 5 parts by weight Silicon dioxide: about 1.5 parts by weight Sodium hydroxide: about 1 part by weight Potassium hydroxide: about 1 part by weight; A pharmaceutical composition comprising as an active therapeutic ingredient a mixture containing trace amounts of zinc and calcium carbonate, further containing a balance of ammonium sulfate, and optionally a pharmaceutically acceptable carrier, excipient or diluent. . 14. Aluminum oxide hydrate: about 17 parts by weight Iron: about 8 parts by weight Magnesium oxide: about 5 parts by weight Silicon dioxide: about 1.5 parts by weight Sodium hydroxide: about 1 part by weight Potassium hydroxide: about 1 part by weight; Animals (other than humans) with arthritis or bursitis are administered an effective amount of a mixture containing trace amounts of zinc and calcium, and also residual amounts of ammonium sulfate.
A method of treating arthritis or bursitis, which consists in giving the drug orally. 15. Aluminum oxide hydrate: about 17 parts by weight Iron: about 8 parts by weight Magnesium oxide: about 5 parts by weight Silicon dioxide: about 1.5 parts by weight Sodium hydroxide: about 1 part by weight Potassium hydroxide: about 1 part by weight; Infectious mononucleosis, consisting of giving internally to an animal with infectious mononucleosis (other than humans) an effective amount of a mixture containing trace amounts of zinc and calcium, and also containing residual amounts of ammonium sulfate. treatment method. 16. Aluminum oxide hydrate: about 17 parts by weight Iron: about 8 parts by weight Magnesium oxide: about 5 parts by weight Silicon dioxide: about 1.5 parts by weight Sodium hydroxide: about 1 part by weight Potassium hydroxide: about 1 part by weight; copper; Treatment of spasmodic colitis, which comprises administering orally to an animal (other than humans) with spasmodic colitis, an effective amount of a mixture containing trace amounts of zinc and calcium and also containing residual amounts of ammonium sulfate. Method of treatment. 17. Aluminum oxide hydrate: about 17 parts by weight Iron: about 8 parts by weight Magnesium oxide: about 5 parts by weight Silicon dioxide: about 1.5 parts by weight Sodium hydroxide: about 1 part by weight Potassium hydroxide: about 1 part by weight; A method for the treatment of emphysema, comprising administering to an animal (other than a human being) with emphysema an effective amount of a mixture containing trace amounts of zinc and calcium and further containing a residual amount of ammonium sulfate. 18. Aluminum oxide hydrate: about 17 parts by weight Iron: about 8 parts by weight Magnesium oxide: about 5 parts by weight Silicon dioxide: about 1.5 parts by weight Sodium hydroxide: about 1 part by weight Potassium hydroxide: about 1 part by weight; copper; Treatment of prostate or bone cancer, comprising administering orally to an animal (other than a human) with prostate or bone cancer, an effective amount of a mixture containing trace amounts of zinc and calcium, and further containing residual amounts of ammonium sulfate. Method of treatment. 19. Aluminum oxide hydrate: about 17 parts by weight Iron: about 8 parts by weight Magnesium oxide: about 5 parts by weight Silicon dioxide: about 1.5 parts by weight Sodium hydroxide: about 1 part by weight Potassium hydroxide: about 1 part by weight; A method for the treatment of cancer, comprising administering to an animal (other than a human being) suffering from cancer an effective amount of a mixture containing trace amounts of zinc and calcium, and further containing residual amounts of ammonium sulfate. 20. Aluminum oxide hydrate: about 17 parts by weight Iron: about 8 parts by weight Magnesium oxide: about 5 parts by weight Silicon dioxide: about 1.5 parts by weight Sodium hydroxide: about 1 part by weight Potassium hydroxide: about 1 part by weight; copper; A method for the treatment of epidermoid carcinoma, comprising administering orally to an animal (other than a human) having epidermoid carcinoma an effective amount of a mixture containing trace amounts of zinc and calcium, and further containing a residual amount of ammonium sulfate.